Fuhong Hanlin (02696.HK): The Phase 1 clinical study of HLX13, a first-line treatment for unresectable advanced hepatocellular carcinoma, completed dosing of the first patient in China.

Zhixin Finance APP News, Fuhong Hanlin (02696.HK) announced that recently, the company's independently developed ipilimumab biosimilar HLX13 (recombinant anti-CTLA-4 fully human monoclonal antibody injection) (HLX13) first-line treatment for unresectable advanced hepatocellular carcinoma (HCC) patients. The 1/3 phase clinical study was completed with the first patient dosed in China.